Evidence map›Paper›PMID 35529389›Full record

ArticleRSC advances2019

Engineering an enhanced thrombin-based GLP-1 analog with long-lasting glucose-lowering and efficient weight reduction.

Hongchao Pan, Yini Xie, Wenying Lu, Yin Chen, Zhao Lu, Jun Zhen, Weiwei Wang, Anquan Shang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Hongchao PanDepartment of Laboratory Medicine, Shanghai Simple Gene Medical Laboratory Shanghai 200025 P.R. China.
Yini XieDepartment of Laboratory Medicine, The People's Hospital of Jiedong Jieyang 515500 P. R. China.
Wenying LuDepartment of Experimental Medicine Center, The Sixth People's Hospital of Yancheng City Yancheng 224001 P. R. China lydia_wangweiwei@sina.com.
Yin ChenKey Laboratory of Biological Medicine, Department of Life Science and Technology, Jinan University 51000 P. R. China.
Zhao LuKey Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University Nanjing 210000 P. R. China.
Jun ZhenKey Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University Nanjing 210000 P. R. China.
Weiwei WangDepartment of Experimental Medicine Center, The Sixth People's Hospital of Yancheng City Yancheng 224001 P. R. China lydia_wangweiwei@sina.com.ORCID https://orcid.org/0000-0002-3366-7886
Anquan ShangDepartment of Laboratory Medicine, Tongji Hospital of Tongji University Shanghai 200065 P. R. China shanganquan@tongji.edu.cn.ORCID https://orcid.org/0000-0003-2820-1982
China Pharmaceutical University · CNInstitute of Experimental Physics of the Slovak Academy of Sciences · SKJinan University · CNTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peptides are considered as potent therapeutic drugs primarily due to the exquisite potency and selectivity to targets. However, the development and clinical application of peptide drugs were severely limited by the poor

Identifiers

PMID35529389
PMCPMC9072222
OpenAlexW2975290917

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.